KR20210107050A - 3.알파.-히드록시-17.베타.-아미드 신경활성 스테로이드 및 그의 조성물 - Google Patents

3.알파.-히드록시-17.베타.-아미드 신경활성 스테로이드 및 그의 조성물 Download PDF

Info

Publication number
KR20210107050A
KR20210107050A KR1020217022533A KR20217022533A KR20210107050A KR 20210107050 A KR20210107050 A KR 20210107050A KR 1020217022533 A KR1020217022533 A KR 1020217022533A KR 20217022533 A KR20217022533 A KR 20217022533A KR 20210107050 A KR20210107050 A KR 20210107050A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
compound
alkyl
independently hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217022533A
Other languages
English (en)
Korean (ko)
Inventor
마리아 지저스 블란코-필라도
프란체스코 지. 살리투로
Original Assignee
세이지 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세이지 테라퓨틱스, 인크. filed Critical 세이지 테라퓨틱스, 인크.
Publication of KR20210107050A publication Critical patent/KR20210107050A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217022533A 2018-12-21 2019-12-20 3.알파.-히드록시-17.베타.-아미드 신경활성 스테로이드 및 그의 조성물 Ceased KR20210107050A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862784229P 2018-12-21 2018-12-21
US201862784222P 2018-12-21 2018-12-21
US62/784,229 2018-12-21
US62/784,222 2018-12-21
PCT/US2019/067953 WO2020132504A1 (en) 2018-12-21 2019-12-20 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof

Publications (1)

Publication Number Publication Date
KR20210107050A true KR20210107050A (ko) 2021-08-31

Family

ID=69591712

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217022533A Ceased KR20210107050A (ko) 2018-12-21 2019-12-20 3.알파.-히드록시-17.베타.-아미드 신경활성 스테로이드 및 그의 조성물

Country Status (12)

Country Link
US (1) US20220372067A1 (cg-RX-API-DMAC7.html)
EP (1) EP3898646B1 (cg-RX-API-DMAC7.html)
JP (2) JP7692830B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210107050A (cg-RX-API-DMAC7.html)
CN (1) CN113195512A (cg-RX-API-DMAC7.html)
AU (2) AU2019403415B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012242A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124371A1 (cg-RX-API-DMAC7.html)
IL (1) IL284183A (cg-RX-API-DMAC7.html)
MX (2) MX2021007504A (cg-RX-API-DMAC7.html)
TW (2) TWI848034B (cg-RX-API-DMAC7.html)
WO (1) WO2020132504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
IL312610B2 (en) 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
CN115768781A (zh) * 2020-06-24 2023-03-07 萨奇治疗股份有限公司 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物
CN119192275B (zh) * 2024-08-22 2025-05-30 湖南玉新药业有限公司 一种3-羰基-4-氮杂-5α-雄甾-17β-羧酸化合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US9512170B2 (en) * 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
DK3258939T3 (da) * 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
IL312610B2 (en) * 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物

Also Published As

Publication number Publication date
MX2021007504A (es) 2021-10-13
TW202438080A (zh) 2024-10-01
JP7858720B2 (ja) 2026-05-14
TWI892697B (zh) 2025-08-01
TWI848034B (zh) 2024-07-11
JP2022514385A (ja) 2022-02-10
CA3124371A1 (en) 2020-06-25
JP7692830B2 (ja) 2025-06-16
EP3898646A1 (en) 2021-10-27
AU2025267433A1 (en) 2025-12-04
WO2020132504A1 (en) 2020-06-25
AU2019403415A1 (en) 2021-07-08
BR112021012242A2 (pt) 2021-09-28
CN113195512A (zh) 2021-07-30
AU2019403415B2 (en) 2025-08-21
TW202038967A (zh) 2020-11-01
US20220372067A1 (en) 2022-11-24
EP3898646B1 (en) 2026-02-18
JP2024107296A (ja) 2024-08-08
MX2025000126A (es) 2025-02-10
IL284183A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
JP7821842B2 (ja) C17、c20、およびc21置換神経刺激性ステロイドおよびそれらの使用方法
JP7858720B2 (ja) 3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物
US11147877B2 (en) Compositions and methods for treating CNS disorders
RU2733756C2 (ru) Композиции и способы для лечения расстройств цнс
JP6742308B2 (ja) Cns障害を処置するための組成物および方法
JP6875996B2 (ja) 神経刺激性ステロイド、組成物、およびその使用
JP7817179B2 (ja) 神経刺激性ステロイド及びその使用方法
JP7857877B2 (ja) 3.アルファ.-ヒドロキシ、17.ベータ.-c(o)-n-アリール置換神経活性ステロイド及びそれらの組成物
KR20200104350A (ko) Cns 장애의 치료를 위한 조성물 및 방법
JP2021510695A (ja) CNS障害の処置における使用のためのアザ、オキサ、およびチア−プレグナン−20−オン−3α−オール化合物
CA3143545A1 (en) Compounds for treating cns disorders
JP2022505146A (ja) 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法
RU2846188C2 (ru) 3альфа-гидрокси-17бета-амидные нейроактивные стероиды и их композиции
RU2828261C2 (ru) С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения
HK40105117A (en) C17, c20, and c21 substituted neuroactive steroids and their methods of use
BR122024007325A2 (pt) Compostos esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida, suas composições farmacêuticas e seus usos
HK40000512B (en) C17, c20, and c21 substituted neuroactive steroids and their methods of use
HK40000512A (en) C17, c20, and c21 substituted neuroactive steroids and their methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000